Zymeworks (FRA:ZA8) Receivables Turnover : 0.40 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zymeworks's Revenue for the three months ended in Mar. 2024 was €9.23 Mil. Zymeworks's average Accounts Receivable for the three months ended in Mar. 2024 was €23.17 Mil. Hence, Zymeworks's Receivables Turnover for the three months ended in Mar. 2024 was 0.40.

Zymeworks Receivables Turnover Historical Data

The historical data trend for Zymeworks's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Receivables Turnover Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

23.30

4.40

1.79

17.17

2.82

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															0.71	0.12	0.29	0.38	0.40

Competitive Comparison of Zymeworks's Receivables Turnover

For the Biotechnology subindustry, Zymeworks's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Zymeworks's Receivables Turnover falls into.

Zymeworks Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Zymeworks's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	69.703	/ (	(31.53	+	17.86)	/	2 )
=	69.703	/	24.695
=	2.82

Zymeworks's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	9.228	/ (	(17.86	+	28.473)	/	2 )
=	9.228	/	23.1665
=	0.40

Zymeworks (FRA:ZA8) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Zymeworks Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Zymeworks's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (FRA:ZA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

ZYME:USA

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines